Vaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $56.83, for a total value of $127,867.50. Following the completion of the transaction, the chief operating officer directly owned 160,744 shares of the company’s stock, valued at approximately $9,135,081.52. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Tuesday, March 10th, Jim Wassil sold 7,395 shares of Vaxcyte stock. The shares were sold at an average price of $58.88, for a total value of $435,417.60.

Vaxcyte Price Performance

PCVX stock traded down $0.31 during midday trading on Friday, reaching $56.93. The company had a trading volume of 696,793 shares, compared to its average volume of 1,332,142. The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of -10.13 and a beta of 1.38. The stock has a 50 day moving average price of $58.73 and a 200-day moving average price of $51.47. Vaxcyte, Inc. has a 1-year low of $28.09 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.34). During the same quarter in the previous year, the company posted ($1.12) earnings per share. As a group, research analysts anticipate that Vaxcyte, Inc. will post -7 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on PCVX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Needham & Company LLC lifted their target price on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. BTIG Research lifted their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vaxcyte currently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Institutional Trading of Vaxcyte

Several hedge funds and other institutional investors have recently made changes to their positions in PCVX. EverSource Wealth Advisors LLC boosted its holdings in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares during the last quarter. CWM LLC increased its stake in Vaxcyte by 9.0% in the 4th quarter. CWM LLC now owns 2,840 shares of the company’s stock valued at $131,000 after buying an additional 234 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Vaxcyte by 0.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 31,274 shares of the company’s stock valued at $1,443,000 after buying an additional 252 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in Vaxcyte by 3.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,083 shares of the company’s stock valued at $465,000 after buying an additional 369 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.